PARP Inhibitors Represent Effective Upfront Ovarian Cancer Treatment Options
May 31st 2023Whitfield B. Growdon, MD, shares the potential implications of first-line PARP maintenance in newly diagnosed ovarian cancer, the importance of treating patients with effective therapies as early as possible, and where combination regimens could fit into the treatment paradigm going forward.
Clinical Trials in Endometrial Cancer Need Improved Diversity to Address Rising Mortality Rates
Bhavana Pothuri, MD, expands on challenges that still need to be addressed for the treatment of patients with endometrial cancer, highlights potential practice-changing data from the phase 3 NRG-GY018 and RUBY trials, details the evolving role of PARP inhibitors for patients with ovarian cancer, and touches on key emerging data from trials for patients with cervical cancer.
EVEREST-1 Trial Seeks to Bring HLA-A*02-directed CAR T to Patients With Solid Tumors
The upcoming phase 1/2 EVEREST-1 trial, where the novel CAR T-cell therapy A2B530 will be evaluated in patients with solid tumors, aims to push progress for one-and-done engineered therapies in this space.
Adjuvant mRNA-4157 Plus Pembrolizumab Improves RFS in Resected High-Risk Melanoma
mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.
CTLA-4–Based Combinations Highlight Evolution of Treatment in Metastatic NSCLC
Vamsidhar Velcheti, MD, highlights the advancement of CTLA-4–based combinations in non–small cell lung cancer treatment, the emergence of antibody-drug conjugates in non–small cell lung cancer, and the impact of the POSEIDON trial on the treatment landscape.